Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exclusive: Abbott taps Morgan Stanley to sell mature products - sources

05/02/2014 | 05:00pm EDT
The corporate logo of financial firm Morgan Stanley is pictured on a building in San Diego

NEW YORK (Reuters) - Abbott Laboratories (>> Abbott Laboratories) is considering selling a big chunk of its mature drugs, joining a list of large drugmakers seeking to sell their older products in an effort to focus on high-growth areas, people familiar with the matter said.

NEW YORK (Reuters) - Abbott Laboratories (>> Abbott Laboratories) is considering selling a big chunk of its mature drugs, joining a list of large drugmakers seeking to sell their older products in an effort to focus on high-growth areas, people familiar with the matter said.

Abbott's portfolio of mature drugs being reviewed for sale has around $2 billion (1.18 billion pounds) in annual revenue and could fetch more than $5 billion, the people said.

The U.S. drugmaker is working with Morgan Stanley (>> Morgan Stanley) to find a buyer for the off-patent, or established products, the people added, asking not to be identified because the matter is confidential. Representatives for Abbott and Morgan Stanley declined to comment.

Abbott has a big lineup of established pharmaceuticals, whose sales fell 3 percent last year to $4.97 billion. Analysts have been grumbling for the past year about the performance of the business, which has dragged down overall company results.

But Abbott Chief Executive Miles White previously expressed faith in the business, and appreciation for the cash flow it provides that can be used to fund research and other company operations.

Abbott's divestiture plans for part of its established products come at a time when its larger competitors are also looking to sell their own line-up of legacy drugs.

U.S. drugmaker Merck & Co (>> Merck & Co., Inc.) is considering selling a big portfolio of mature drugs that could fetch more than $15 billion, Reuters reported on Wednesday.

French pharmaceutical company Sanofi SA (>> SANOFI) has also been talking to buyers about selling $7 billion to $8 billion worth of mature products in the past few months, people familiar with the matter told Reuters earlier this week.

Those drug portfolios would provide good acquisition opportunities for generic drugmakers and specialty pharmaceutical companies, including Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc), Actavis Plc (>> Actavis PLC) and Mylan Inc (>> Mylan Inc), people familiar with the matter and analysts said.

Faced with healthcare spending cuts and generic competition, the pharmaceutical industry is undergoing a major restructuring, with companies playing to their strengths by building up certain businesses and divesting others.

Pfizer Inc (>> Pfizer Inc.), which spun off its animal health and infant formula businesses in recent years, is also considering whether to divest the hundreds of off-patent drugs that are mostly sold in emerging markets. But Pfizer has said it would be unable to do so until 2017, after the company has better examined the unit's financial performance.

Merck's plan to sell its established products is "highly consistent" with the company's refocusing strategy and could allow for more meaningful earnings growth, JPMorgan analyst Chris Schott said in a research note on Thursday.

(Additional reporting by Ransdell Pierson in New York; editing by Matthew Lewis)

By Soyoung Kim and Olivia Oran


ę Reuters 2014
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 0.47% 121.09 Delayed Quote.10.07%
MERCK & CO., INC. -1.79% 76.93 Delayed Quote.-4.24%
MORGAN STANLEY 0.95% 96.28 Delayed Quote.40.19%
SANOFI -1.22% 86.52 Real-time Quote.11.30%
All news about ABBOTT LABORATORIES
09:01aNEW STUDY : Half of Americans Living with Diabetes May be Consuming Less Than th..
PR
07/27Global markets live: LVMH, Michelin, Tesla, Amazon, Activision...
07/23ABBOTT LABORATORIES : Jefferies & Co Adjusts Abbott Laboratories PT to $135 From..
MT
07/23ABBOTT LABORATORIES : JPMorgan Adjusts Abbott Laboratories PT to $135 From $122,..
MT
07/23ABBOTT LABORATORIES : Morgan Stanley Adjusts Abbott Laboratories PT to $136 From..
MT
07/23ABBOTT LABORATORIES : Raymond James Adjusts Price Target on Abbott Laboratories ..
MT
07/23ABBOTT LABORATORIES : Credit Suisse Raises Abbott Laboratories' PT to $130 from ..
MT
07/23ABBOTT LABORATORIES : UBS Adjusts Abbott Laboratories' PT to $131 From $127, Cit..
MT
07/23ANALYST RECOMMENDATIONS : Apple, Aviva, Biogen, Comerica Incorporated, Tesla...
07/22GLOBAL MARKETS LIVE : AT&T, American Airlines, Biogen, Netflix, ABB...
More news
Financials (USD)
Sales 2021 39 766 M - -
Net income 2021 5 967 M - -
Net Debt 2021 8 719 M - -
P/E ratio 2021 35,9x
Yield 2021 1,42%
Capitalization 214 B 214 B -
EV / Sales 2021 5,60x
EV / Sales 2022 5,56x
Nbr of Employees 109 000
Free-Float 89,0%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 120,52 $
Average target price 128,81 $
Spread / Average Target 6,88%
EPS Revisions
Managers and Directors
Robert B. Ford President, CEO, Chief Operating Officer & Director
Robert Emmett Funck Chief Financial Officer & Executive Vice President
Miles D. White Executive Chairman
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Roxanne Schuh Austin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES10.07%214 142
MEDTRONIC PLC11.42%175 406
BECTON, DICKINSON AND COMPANY1.30%73 717
SARTORIUS STEDIM BIOTECH61.47%51 173
HOYA CORPORATION8.86%50 531
ALIGN TECHNOLOGY, INC.16.37%49 213